Ailton Antonio Sousa-Junior

Dr. Ailton Antonio Sousa-Junior

FarmaTec - Laboratory of Pharmaceutical Technology, Federal University of Goias, Goiânia, Goiás, Brazil
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RORelton Romeis Oliveira
Relton Romeis Oliveira
ECEmílio R. Cintra
Emílio R. Cintra
Ailton Antonio Sousa-JuniorAilton Antonio Sousa-Junior
Ailton Antonio Sousa-Junior
LMLarissa C. Moreira
Larissa C. Moreira
ASArtur C. G. da Silva
Artur C. G. da Silva
ELEliana Martins Lima
Eliana Martins Lima
Melanoma is the most aggressive and metastasis-prone form of skin cancer. Conventional therapies include chemotherapeutic agents, either as small molecules or carried by FDA-approved nanostructures. However, systemic toxicity and side effects still remain as major drawbacks. With the advancement of nanomedicine, new delivery strategies emerge at a regular pace, aiming to overcome these challenges. Stimulus-responsive drug delivery systems might considerably reduce systemic toxicity and side-effects by limiting drug release to the affected area. Herein, we report the development of paclitaxel-loaded lipid-coated manganese ferrite magnetic nanoparticles (PTX-LMNP) as magnetosomes synthetic analogs, envisaging the combined chemo-magnetic hyperthermia treatment of melanoma. PTX-LMNP physicochemical properties were verified, including their shape, size, crystallinity, FTIR spectrum, magnetization profile, and temperature profile under magnetic hyperthermia (MHT). Their diffusion in porcine ear skin (a model for human skin) was investigated after intradermal administration via fluorescence microscopy. Cumulative PTX release kinetics under different temperatures, either preceded or not by MHT, were assessed. Intrinsic cytotoxicity against B16F10 cells was determined via neutral red uptake assay after 48 h of incubation (long-term assay), as well as B16F10 cells viability after 1 h of incubation (short-term assay), followed by MHT. PTX-LMNP-mediated MHT triggers PTX release, allowing its thermal-modulated local delivery to diseased sites, within short timeframes. Moreover, half-maximal PTX inhibitory concentration (IC50) could be significantly reduced relatively to free PTX (142,500×) and Taxol® (340×). Therefore, the dual chemo-MHT therapy mediated by intratumorally injected PTX-LMNP stands out as a promising alternative to efficiently deliver PTX to melanoma cells, consequently reducing systemic side effects commonly associated with conventional chemotherapies.

1 September 2018 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
KRKalline L. Ribeiro
Kalline L. Ribeiro
IFIsaac A.M. Frías
Isaac A.M. Frías
Octavio FrancoOctavio Franco
Octavio Franco
SDSimoni C. Dias
Simoni C. Dias
Ailton Antonio Sousa-JuniorAilton Antonio Sousa-Junior
Ailton Antonio Sousa-Junior
CACésar Augusto Souza de Andrade
César Augusto Souza de Andrade

18 June 2018 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
LMLázaro Moreira Marques-Neto
Lázaro Moreira Marques-Neto
NZNicholas Zufelato
Nicholas Zufelato
Ailton Antonio Sousa-JuniorAilton Antonio Sousa-Junior
Ailton Antonio Sousa-Junior
MTMonalisa Martins Trentini
Monalisa Martins Trentini
ACAdeliane Castro da Costa
Adeliane Castro da Costa
AJAna Paula Junqueira-Kipnis
Ana Paula Junqueira-Kipnis
Metal-based nanoparticles (NPs) stimulate innate immunity; however, they have never been demonstrated to be capable of aiding the generation of specific cellular immune responses. Therefore, our objective was to evaluate whether iron oxide-based NPs have adjuvant properties in generating cellular Th1, Th17 and TCD8 (Tc1) immune responses. For this purpose, a fusion protein (CMX) composed of Mycobacterium tuberculosis antigens was used as a subunit vaccine. Citrate-coated MnFe2O4 NPs were synthesized by co-precipitation and evaluated by transmission electron microscopy. The vaccine was formulated by homogenizing NPs with the recombinant protein, and protein corona formation was determined by dynamic light scattering and field-emission scanning electron microscopy. The vaccine was evaluated for the best immunization route and strategy using subcutaneous and intranasal routes with 21-day intervals between immunizations. When administered subcutaneously, the vaccine generated specific CD4+IFN-γ+ (Th1) and CD8+IFN-γ+ responses. Intranasal vaccination induced specific Th1, Th17 (CD4+IL-17+) and Tc1 responses, mainly in the lungs. Finally, a mixed vaccination strategy (2 subcutaneous injections followed by one intranasal vaccination) induced a Th1 (in the spleen and lungs) and splenic Tc1 response but was not capable of inducing a Th17 response in the lungs. This study shows for the first time a subunit vaccine with iron oxide based NPs as an adjuvant that generated cellular immune responses (Th1, Th17 and TCD8), thereby exhibiting good adjuvant qualities. Additionally, the immune response generated by the subcutaneous administration of the vaccine diminished the bacterial load of Mtb challenged animals, showing the potential for further improvement as a vaccine against tuberculosis.

14 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ailton Antonio Sousa-JuniorAilton Antonio Sousa-Junior
Ailton Antonio Sousa-Junior
FMFrancyelli Mello-Andrade
Francyelli Mello-Andrade
JRJoão Victor Ribeiro Rocha
João Victor Ribeiro Rocha
THTacio Gonçalves Hayasaki
Tacio Gonçalves Hayasaki
JCJuliana Santana de Curcio
Juliana Santana de Curcio
ABAndris Bakuzis
Andris Bakuzis
Inducing immunogenic cell death (ICD) during cancer therapy is a major challenge that might significantly improve patient survival. The purpose of this study was to develop a theranostic nanocarrier, capable both of conveying a cytotoxic thermal dose when mediating photothermal therapy (PTT) after its intravenous delivery, and of consequently inducing ICD, improving survival. The nanocarrier consists of red blood cell membranes (RBCm) embedding the near-infrared dye IR-780 (IR) and camouflaging Mn-ferrite nanoparticles (RBCm-IR-Mn). The RBCm-IR-Mn nanocarriers were characterized by size, morphology, surface charge, magnetic, photophysical, and photothermal properties. Their photothermal conversion efficiency was found to be size- and concentration-dependent. Late apoptosis was observed as the cell death mechanism for PTT. Calreticulin and HMGB1 protein levels increased for in vitro PTT with temperature around 55 °C (ablative regime) but not for 44 °C (hyperthermia), suggesting ICD elicitation under ablation. RBCm-IR-Mn were then intravenously administered in sarcoma S180-bearing Swiss mice, and in vivo ablative PTT was performed five days later. Tumor volumes were monitored for the subsequent 120 days. RBCm-IR-Mn-mediated PTT promoted tumor regression in 11/12 animals, with an overall survival rate of 85% (11/13). Our results demonstrate that the RBCm-IR-Mn nanocarriers are great candidates for PTT-induced cancer immunotherapy.

18 April 2019 in IEEE Transactions on Nanobioscience
Verified
Journal Article
Closed access
GSGuilherme Soares
Guilherme Soares
APANDRE GONCALVES Prospero
ANDRE GONCALVES Prospero
MCMarcos F. Calabresi
Marcos F. Calabresi
DRDiego Rodrigues
Diego Rodrigues
LSLuis G. Simoes
Luis G. Simoes
JMJose R. A. Miranda
Jose R. A. Miranda
In this paper, the application of a technique to evaluate in vivo biodistribution of magnetic nanoparticles (MNP) is addressed: the Multichannel AC Biosusceptometry System (MC-ACB). It allows real-time assessment of magnetic nanoparticles in both bloodstream clearance and liver accumulation, where a complex network of inter-related cells is responsible for MNP uptake. Based on the acquired MC-ACB images, we propose a mathematical model to help understand the distribution and accumulation pharmacokinetics of MNP. MC-ACB showed a high time resolution to detect and monitor MNP, providing sequential images over the particle biodistribution. Utilizing the MC-ACB instrument, we assessed regions corresponding to the heart and liver, and we determined the MNP transfer rates between the bloodstream and the liver. The pharmacokinetic model resulted in having a strong correlation with the experimental data, suggesting that the MC-ACB is a valuable and accessible imaging device to assess in vivo and real-time pharmacokinetic features of MNP.

Verified
Journal Article
Open access
PDF file
Ailton Antonio Sousa-JuniorAilton Antonio Sousa-Junior
Ailton Antonio Sousa-Junior
CYChun Ting Yang
Chun Ting Yang
PKPreethi Korangath
Preethi Korangath
Robert IvkovRobert Ivkov
Robert Ivkov
ABAndris Bakuzis
Andris Bakuzis
A promise of cancer nanomedicine is the “targeted” delivery of therapeutic agents to tumors by the rational design of nanostructured materials. During the past several decades, a realization that in vitro and in vivo preclinical data are unreliable predictors of successful clinical translation has motivated a reexamination of this approach. Mathematical models of drug pharmacokinetics (PK) and biodistribution (BD) are essential tools for small-molecule drugs development. A key assumption underlying these models is that drug-target binding kinetics dominate blood clearance, hence recognition by host innate immune cells is not explicitly included. Nanoparticles circulating in the blood are conspicuous to phagocytes, and inevitable interactions typically trigger active biological responses to sequester and remove them from circulation. Our recent findings suggest that, instead of referring to nanoparticles as designed for active or passive “tumor targeting”, we ought rather to refer to immune cells residing in the tumor microenvironment (TME) as active or passive actors in an essentially “cell-mediated tumor retention” process that competes with active removal by other phagocytes. Indeed, following intravenous injection, nanoparticles induce changes in the immune compartment of the TME because of nanoparticle uptake, irrespective of the nature of tumor targeting moieties. In this study, we propose a 6-compartment PK model as an initial mathematical framework for modeling this tumor-associated immune cell-mediated retention. Published in vivo PK and BD results obtained with bionized nanoferrite® (BNF®) nanoparticles were combined with results from in vitro internalization experiments with murine macrophages to guide simulations. As a preliminary approximation, we assumed that tumor-associated macrophages (TAMs) are solely responsible for active retention in the TME. We model the TAM approximation by relating in vitro macrophage uptake to an effective macrophage avidity term for the BNF® nanoparticles under consideration.